News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Tarek Sahmoud, MD

Articles by Tarek Sahmoud, MD

20 TIP ELONA: An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor– Positive, Progesterone Receptor– Positive, HER2-Negative Advanced or Metastatic Breast Cancer

ByErika P. Hamilton, MD,Lajos Pusztai, MD, DPhil,Hatem Soliman, MD,Sara A. Hurvitz, MD,Krzysztof J. Grzegorzewski,Nassir Habboubi,Priya Marreddy,Tarek Sahmoud, MD,Nuhad Ibrahim, MD

April 28th 2023

21 TIP ELECTRA: An Open- Label, Multicenter, Phase 1b/2 Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), in Combination With Abemaciclib in Patients With Brain Metastasis From Estrogen Receptor–Positive (ER+), HER2– Negative (HER2–) Breast Cancer

ByErika P. Hamilton, MD,Sung-Bae Kim,Neelima Vidula, MD,Simona Scartoni,Tarek Sahmoud, MD,Bartomeu Piza Vallespir,Kathy Puyana Theall,Nassir Habboubi,Nuhad Ibrahim, MD

April 27th 2023

55 TIP ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Women and Men With Metastatic Breast Cancer (mBC)

ByHope S. Rugo, MD,Aditya Bardia, MD, MPH, FASCO,Javier Cortes,Giuseppe Curigliano,Erika P. Hamilton, MD,Sara A. Hurvitz, MD,Sibylle Loibl,Simona Scartoni,Tarek Sahmoud, MD,Krzysztof J. Grzegorzewski,Nassir Habboubi,Joyce A. O’Shaughnessy

April 27th 2023

Cisplatin/Paclitaxel vs Cisplatin/Teniposide for Advanced Non-Small-Cell Lung Cancer

ByGiuseppe Giaccone, MD, PhD,Pieter E. Postmus, MD, PhD,Ted A. W. Splinter, MD,Maria Diaz-puente, MD,Nico Van Zandwijk, MD, PhD,Giorgio V. Scagliotti, MD, PhD,Andrea Ardizzoni, MD,Jan Van Meerbeeck, MD,Channa Debruyne, MD,Tarek Sahmoud, MD

April 1st 1997

A total of 332 patients with advanced non-small-cell lung cancer were randomized by the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative

Latest Updated Articles

Cisplatin/Paclitaxel vs Cisplatin/Teniposide for Advanced Non-Small-Cell Lung Cancer
Published: April 1st 1997 | Updated:

Trending on CancerNetwork

All-Oral Revumenib Regimen May Show Advantage in Newly Diagnosed AML

Blinatumomab/Ponatinib Provides Chemo-Free Option in Ph+ ALL

Talquetamab Combo Yields Responses in Multiple Myeloma With True EMD

SC Cevostamab Highly Active in BCMA-Naive R/R Multiple Myeloma

Linvoseltamab Yields High Response in Newly Diagnosed Multiple Myeloma

© 2025 MJH Life Sciences^®

All rights reserved.